9. Neurohormones versus placebo: irritability results that could not be used in the meta‐analyses.

Study name	Short‐/medium‐/long‐term outcomes	Group 1 sample size	Group 2 sample size	Group 1 results Mean (standard deviation)	Group 2 results Mean (standard deviation)	Other data	Notes
Levy 2003	Short‐term (single‐dose secretin (2 CU/kg))	31	31	0.01 (1.35)	−0.18 (0.79)	‐	Skewed
Squassante 2018	Short‐term balovaptan 1.5 mg	32	23	−1.99 (14.92)	−2.85 (24.29)	‐	Skewed
	Short‐term balovaptan 4 mg	77	22	−1.64 (24.15)	−1.07 (4.95)
	Short‐term balovaptan 10 mg	39	22	−3.42 (34.79)	−2.99 (9.49)
Unis 2002	Short‐term synthetic secretin (single infusion of 0.4 μg/kg)	23	15	−1.3 (3.93)	−1.5 (3.38)	‐	Skewed